Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | STAT1 | P42224 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 9/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | ACHE | P22303 | 6/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.36 |
| ▸ | BCHE | P06276 | 3/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2546977 | 0.93 | TRPV1 (0.38) | LMNASMN1; SMN2TRPV1MAPT | |
| SCHEMBL2541766 | 0.92 | LMNA (0.36) | RAB9ALMNASTAT1SMN1; SMN2TRPV1 | |
| SCHEMBL2548141 | 0.89 | ACHE (0.43) | RAB9ALMNASTAT1SMN1; SMN2ACHE | |
| SCHEMBL2547349 | 0.87 | SMN1; SMN2 (0.45) | RAB9ALMNASTAT1SMN1; SMN2NPC1 | |
| SCHEMBL2547868 | 0.85 | ACHE (0.40) | RAB9ALMNASTAT1SMN1; SMN2ACHE | |
| SCHEMBL2541718 | 0.85 | ACHE (0.37) | RAB9ALMNASTAT1SMN1; SMN2NPC1 | |
| SCHEMBL2540184 | 0.85 | SMN1; SMN2 (0.36) | LMNASMN1; SMN2TRPV1MAPT | |
| SCHEMBL2544861 | 0.84 | ACHE (0.36) | RAB9ALMNASTAT1SMN1; SMN2TRPV1 | |
| SCHEMBL2547266 | 0.83 | ABL1 (0.37) | RAB9ASMN1; SMN2TRPV1NPC1MAPT | |
| SCHEMBL2547156 | 0.83 | TRPV1 (0.33) | RAB9ALMNASTAT1SMN1; SMN2TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110263593-A1 | NOVEL IMIDAZO[1,2-a]PYRIMIDINE DERIVATIVES, METHOD FOR THE PREPARATION THEREOF, USE THEREOF AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE, IN PARTICULAR AS MET INHIBITORS | SANOFI-AVENTIS (FR) | 2011-10-27 | — | — | US | disclosed |
| CN-102159577-A | Imidazo [1,2-a ] pyrimidine derivatives, process for their preparation, their use as medicaments, pharmaceutical compositions and as MET inhibitors | SANOFI AVENTIS | 2011-08-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263593-A1 | NOVEL IMIDAZO[1,2-a]PYRIMIDINE DERIVATIVES, METHOD FOR THE PREPARATION THEREOF, USE THEREOF AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE, IN PARTICULAR AS MET INHIBITORS | TPMT, MET, PAICS | RAB9A 2193/4885LMNA 4476/4885STAT1 2289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.